Inbiogen Secures Management Rights of Haimbio... "Aiming for Successful Development of Major Anticancer Drugs"

[Asia Economy Reporter Hyunseok Yoo] Inbiogen announced on the 12th that at the ‘Haim Bio Extraordinary General Meeting of Shareholders’ held in Jongno-gu on the morning of the 12th, CEO Kang Ji-yeon, Vice President Lee Jon-adan, and Director Kim Nam-gyun were appointed as inside directors of Haim Bio, and lawyer Lee Jung-hee was appointed as an outside director.

As a result of this extraordinary general meeting, the plan is to quickly normalize the management of Haim Bio, which had been operated inefficiently, and to accelerate the successful completion of clinical trials for the anti-cancer drug Starvenib.

Previously, Inbiogen invested 5 billion KRW in Haim Bio to become the largest shareholder. Kang Ji-yeon, CEO of Inbiogen, said, “We will build a company that raises the status of K-Bio,” adding, “We will focus on the growth potential of the bio business and strive to secure a sustainable pipeline.”

This content was produced with the assistance of AI translation services.